Proceedings · Session S-944 · filed November 19, 2026

Lab Technology & MethodsSession paper

AMCAP one-pot mRNA process wins CPHI manufacturing award

Anemocyte’s AMCAP won a CPHI manufacturing award in October 2026, but the interview offers no batch data, yield or purity figures to quantify its claimed contaminant reduction.

By Rebecca Stone4 min read788 words

Summary

  • October 2026: Anemocyte won the CPHI Award for Manufacturing Excellence at CPHI Milan for AMCAP.
  • LC-MS resolves three states—Cap0, Cap1 and uncapped mRNA—after cleavage at the 5′ end.
  • A single-methyl-group resolution gap prevents capillary electrophoresis from distinguishing Cap0 from Cap1.
  • AMCAP runs capping and transcription in one pot, avoiding repeated enzyme additions.
  • The source reports no batch size, yield, purity percentage, recovery rate or cost.
<![CDATA[Analytics and Upstream Process Design for mRNA Synthesis]]>
Figure<![CDATA[Analytics and Upstream Process Design for mRNA Synthesis]]> — 652234 / pixabay

By Rebecca Stone

Anemocyte won the CPHI Award for Manufacturing Excellence at CPHI Milan in October 2026 for AMCAP, a one-pot messenger RNA (mRNA) synthesis process. The award supplies a dated milestone, but the interview discloses no batch count, yield, cost, purity percentage or independent comparison, so the claimed process advantage remains unquantified.

What analytical method can measure mRNA capping?

At Anemocyte, a biotech manufacturing organization specializing in contract development and manufacturing of plasmids, Marco Pupo, PhD, serves as innovation and development coordinator. He identifies liquid chromatography coupled to mass spectrometry (LC-MS) as the “gold standard for capping quantification.”

The method cleaves a short fragment from the 5′ end of mRNA and separates Cap0, Cap1 (the two capped structures in the assay) and uncapped material. For a laboratory manager, that capability makes the instrument and trained analyst a combined capital and staffing decision, although the source gives neither an instrument price nor a method-validation cost.

The alternatives have narrower analytical scopes:

  • Capillary electrophoresis (CE) cannot resolve a single methyl group, so it cannot distinguish Cap0 from Cap1.
  • Standard enzymatic assays report capped versus uncapped mRNA but cannot discriminate between the two capped structures.

Those limits matter when a development team needs to compare cap species rather than merely confirm that a transcript carries a cap. Pupo nevertheless maintains that mass spectrometry remains “the method of choice,” despite its cost and requirement for highly skilled analysts. The alternatives therefore narrow measurement scope rather than replace LC-MS with an equivalent assay.

How does AMCAP reduce upstream contamination?

Pupo argues that minimizing upstream steps offers the most effective way to limit contaminants in mRNA synthesis. His target list includes double-stranded RNA (dsRNA), residual enzymes and reagents, and unincorporated nucleotides. The design logic is to reduce opportunities for contamination before downstream purification begins.

The source credits nucleocapsid protein (NCAP) with reducing the number of upstream steps in mRNA synthesis. Anemocyte also designed a buffer and reaction conditions intended to suppress dsRNA formation, with salt concentration and use of a low double-strand polymerase contributing to that aim.

AMCAP then consolidates capping and transcription in one pot. The streamlined protocol avoids repeated enzyme additions, which limits residual enzyme and reagent accumulation and makes the remaining material easier to clear. Synchronizing the two reactions allows consumption kinetics to run more completely, reducing the risk of leftover free nucleotides, S-adenosylmethionine byproducts and capping reagents.

These are risk-reduction statements, not measured clearance values. The source does not report how much dsRNA, enzyme, reagent or nucleotide the process removes, nor does it provide a side-by-side result against a more step-intensive route. The practical comparison claimed is structural: fewer upstream steps and fewer repeated additions versus more repeated handling.

What downstream purification can remove residual material?

Several commercial downstream options exist, most based on chromatography or filtration. Cited chromatography modes include affinity and hydrophobic interaction, while tangential flow filtration (TFF) is the most important option in Pupo’s account.

He combines this downstream stage with AMCAP to argue that the resulting mRNA is highly pure and almost entirely free of contaminants. That is the interview’s strongest performance claim, but no acceptance criterion supports it in the supplied material.

The source gives no residual-impurity values, recovery rate, batch scale, named purification product or independent-laboratory result. It also does not state whether measurements came from development batches, good manufacturing practice (GMP) batches or both.

What does the speaker’s role establish?

Pupo brings more than a decade of academic and industry experience in biotechnology R&D, with a background in Pharmaceutical Technology and Biochemistry. He has coordinated cross-functional teams in matrixed organizations and overseen international programs from proof of concept to GMP technology transfer.

His stated specialties include process and analytical development for non-viral cell therapies, proteins and nucleic-acid therapeutics. His biography also identifies him as an expert inventor who pioneered single-pot and simultaneous co-transcriptional in vitro capping technologies (capping performed during transcription), including AMCAP, to ease scale-up and reduce manufacturing bottlenecks for therapeutic mRNA.

That background establishes technical involvement, not independent performance data. The source gives no sample size, assay precision, yield, funding source or external review. Because Pupo is both a company coordinator and an inventor associated with the method, his conclusions amount to informed company testimony, not a controlled comparison.

What should R&D teams test next?

For R&D leaders considering AMCAP or a comparable in vitro capping workflow, the next investment gate should be batch-level LC-MS and contaminant data covering yield, recovery, purity and cost; until those figures exist under comparable conditions, the October 2026 award marks manufacturing promise rather than verified process performance.

via pharmtech.com (Source)

Filed under

  • mrna-manufacturing
  • one-pot-synthesis
  • mrna-capping
  • lc-ms-analysis
  • downstream-purification
Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Market editor covering regulation, policy and their impact on research and development at Hypothesis Wire.

278 articles

References

  1. Anemocyte wins CPHI 2026 award for one-pot GMP mRNA method
  2. Apertura Opens Its AAV Capsid Playbook to Wider Access
  3. WHO's 15-Partner mRNA Programme Tests the Industry's Manufacturing Playbook
  4. JNC Reports 91% Virus Recovery with Large-Pore Cellulose Resin at BPI 2026
  5. IMU targets 100 million data points per sample across 80,000 UK Biobank donors

« Previous articleNext article »